75 , e13988 (2021)
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention
In summary, the harsh metabolic landscape of the TME, characterized by nutrient competition, accumulation of immunosuppressive metabolites, and dysregulated lipid and amino acid metabolism, severely impairs the function and fate of infiltrating immune cells, ultimately promoting tumor immune evasion and progression
Clinical trials tested doses up to 1mg daily without significant adverse effects, but this does not mean higher doses produce better results or that exceeding researched doses is safe
Theres also the possibility of insulin resistancethe bodys lowered ability to regulate blood sugarwhich comes with its own metabolic risk factors, like kidney disease and type 2 diabetes